ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Nicox Sa

Nicox Sa (0RCQ)

5,67
0,00
( 0,00% )
Aktualisiert: 01:00:00

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Current Price
5,67
Gebot
5,53
Fragen
5,81
Volumen
446
0,00 Tagesbereich 0,00
5,67 52-Wochen-Bereich 5,67
Marktkapitalisierung
Handelsende
5,67
Handelsbeginn
-
Letzte Trade
32
@
0.304
(O)
Letzter Handelszeitpunkt
09:30:33
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
7.505
Ausgegebene Aktien
50.170.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-13,62
Gewinn pro Aktie (EPS)
-0,42
Erlöse
7,14M
Nettogewinn
-20,88M

Über Nicox Sa

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Antibes, Alpes-maritimes, Fra
Gegründet
-
Nicox Sa is listed in the Pharmaceutical Preparations sector of the Londoner Börse with ticker 0RCQ. The last closing price for Nicox was 5,67 €. Over the last year, Nicox shares have traded in a share price range of 5,67 € to 5,67 €.

Nicox currently has 50.170.000 shares in issue. The market capitalisation of Nicox is 284,46 € million. Nicox has a price to earnings ratio (PE ratio) of -13.62.

0RCQ Neueste Nachrichten

Nicox confirme son éligibilité au PEA-PME

Nicox confirme son éligibilité au PEA-PME Communiqué de presseNicox confirme son éligibilité au PEA-PME22 janvier 2025 – publication à 7H30Sophia Antipolis, FranceNicox SA (Euronext Growth Paris :...

Nicox : Point d’activité et résumé financier du quatrième trimestre 2024

Nicox : Point d’activité et résumé financier du quatrième trimestre 2024 Communiqué de presseNicox : Point d’activité et résumé financier du quatrième trimestre 2024  Recrutement du dernier...

Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights

Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Press Release Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Last patient recruited in the...

Nicox annonce la première vente commerciale de ZERVIATE en Chine par son partenaire Ocumension, création d’une nouvelle source de revenus récurrents

Nicox annonce la première vente commerciale de ZERVIATE en Chine par son partenaire Ocumension, création d’une nouvelle source de revenus récurrents Communiqué de presseNicox annonce la première...

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream Press Release Nicox Announces First Commercial Sale of ZERVIATE in China...

Nicox : Recrutement de patients achevé plus tôt que prévu en Chine dans l’étude clinique de phase 3 Denali sur NCX 470

Nicox : Recrutement de patients achevé plus tôt que prévu en Chine dans l’étude clinique de phase 3 Denali sur NCX 470 Communiqué de presseNicox : Recrutement de patients achevé plus tôt que prévu...

Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected

Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Press ReleaseNicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Confirms...

Nicox annonce la publication de la partie adaptive de l’étude clinique de phase 3 Mont Blanc sur NCX 470

Nicox annonce la publication de la partie adaptive de l’étude clinique de phase 3 Mont Blanc sur NCX 470 Communiqué de presseNicox annonce la publication de la partie adaptive de l’étude clinique...

Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial

Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial Press Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc...

Nicox : Point financier sur le troisième trimestre 2024 et résultats financiers du premier semestre 2024

Nicox : Point financier sur le troisième trimestre 2024 et résultats financiers du premier semestre 2024 Communiqué de presseNicox : Point financier sur le troisième trimestre 2024 et résultats...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1005.675.675.6710565.67DE
4005.675.675.6730265.67DE
12005.675.675.6775055.67DE
26005.675.675.6766025.67DE
52005.675.675.6733425.67DE
156005.675.675.6728325.67DE
260005.675.675.6728325.67DE

0RCQ - Frequently Asked Questions (FAQ)

What is the current Nicox share price?
The current share price of Nicox is 5,67 €
How many Nicox shares are in issue?
Nicox has 50.170.000 shares in issue
What is the market cap of Nicox?
The market capitalisation of Nicox is EUR 284,46M
What is the 1 year trading range for Nicox share price?
Nicox has traded in the range of 5,67 € to 5,67 € during the past year
What is the PE ratio of Nicox?
The price to earnings ratio of Nicox is -13,62
What is the cash to sales ratio of Nicox?
The cash to sales ratio of Nicox is 39,85
What is the reporting currency for Nicox?
Nicox reports financial results in EUR
What is the latest annual turnover for Nicox?
The latest annual turnover of Nicox is EUR 7,14M
What is the latest annual profit for Nicox?
The latest annual profit of Nicox is EUR -20,88M
What is the registered address of Nicox?
The registered address for Nicox is SUNDESK SOPHIA ANTIPOLIS ,EMERALD SQUARE, B��TIMENT C, RUE EVARISTE GALOIS, BIOT, ANTIBES, ALPES-MARITIMES, 06410
What is the Nicox website address?
The website address for Nicox is www.nicox.com
Which industry sector does Nicox operate in?
Nicox operates in the PHARMACEUTICAL PREPARATIONS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
IMMImmupharma Plc
4,90p
(20,99%)
6,08M
DKEDukemount Capital Plc
0,041p
(20,59%)
78,26M
GOODGood Energy Group Plc
475,00p
(20,25%)
240,08k
TGPTekmar Group Plc
6,75p
(17,39%)
891,87k
CHFChesterfield Resources Plc
0,35p
(15,89%)
1
OBIOndine Biomedical Inc.
11,25p
(-11,76%)
850,01k
GENIGenincode Plc
4,25p
(-11,46%)
460,85k
0R1OAmazon.com Inc
US$ 215,50
(-9,83%)
3,12k
BELLBelluscura Plc
7,25p
(-9,38%)
126,17k
AWEAlphawave Ip Group Plc
138,00p
(-9,21%)
782,68k
UKOGUk Oil & Gas Plc
0,0225p
(4,65%)
467,96M
TRPTower Resources Plc
0,0295p
(0,00%)
91,11M
INSPInspirit Energy Holdings Plc
0,0025p
(4,17%)
85,2M
DKEDukemount Capital Plc
0,041p
(20,59%)
78,26M
SYMESupply@me Capital Plc
0,0029p
(0,00%)
64,46M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock